ANRIL and atherosclerosis. (8th November 2019)

• Record Type: Journal Article
• Authors: Chen, Li; Qu, Hua; Guo, Ming; Zhang, Ying; Cui, Yuanyuan; Yang, Qiaoning; Bai, Ruina; Shi, Dazhuo
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 45:Number 2(2020)
• Page Start: 240
• Page End: 248
• Publication Date: 2019-11-08
• Subjects: ANRIL -- atherosclerosis -- biomarker -- mechanism; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.13060
• Languages: English
• ISSNs: 0269-4727

Abstract

Abstract: What is known and objective: The 3.8‐kb‐long antisense non‐coding RNA at the INK4 locus (ANRIL) is transcribed from the short arm of human chromosome 9 on P21 and is associated with malfunction of the vascular endothelium, vascular smooth muscle cell (VSMC) proliferation/migration/senescence/apoptosis, mononuclear cell adhesion and proliferation, glycolipid metabolism disorder and DNA damage. Hence, ANRIL plays an important role in atherogenesis. Moreover, genome‐wide association studies (GWAS) have identified ANRIL as a biomarker that is closely related to coronary heart disease (CHD). The objective of this review was to discuss the pathological mechanism of ANRIL in atherosclerotic development and its significance as a predictor of cardiovascular disease. Methods: Review of the PubMed, EMBASE and Cochrane databases for articles demonstrating the roles of ANRIL in the development of atherosclerotic diseases. Results and discussion: The abnormal expression of ANRIL is linked to vascular endothelium injury; the proliferation, migration, senescence and apoptosis of VSMCs; mononuclear cell adhesion and proliferation; glycolipid metabolism disorder; DNA damage; and competing endogenous RNAs. Moreover, ANRIL accelerates the progression of CHD by regulating its single nucleotide polymorphisms (SNPs). What is new and conclusion: Considering that ANRIL accelerates atherosclerosis (AS) development and is a risk factor for CHD, it is reasonable for us to explore an efficacious ANRIL‐based therapy for AS in CHD. Abstract : The abnormal expression of ANRIL promotes the development of atherosclerosis and ANRIL is novel biomarker closely associted with coronary heart disease.